商標名 Etoposide Intravenous Infusion 100mg [SANDOZ] 一般名 エトポシド（Etoposide） 化学名 （5R,5aR,8aR,9S）-9-｛［4,6-O-（1R）-Ethylidene-β-D-glucopyranosyl］oxy｝-5-（4-hydroxy-3,5-dimethoxyphenyl）-5,8,8a,9-tetrahydrofuro［3',4'：6,7］naphtho［2,3-d］［1,3］dioxol-6（5aH）-one 分子式 C29H32O13 分子量 588.56 *構造式 *性状 白色の結晶又は結晶性の粉末である。 メタノールにやや溶けにくく、エタノール（99.5）に溶けにくく、水に極めて溶けにくい。 *融点 約260℃（分解） 取扱い上の注意 安定性試験2） 最終包装製品を用いた加速試験（40±1℃、相対湿度75±5％、6ヵ月）の結果、エトポシド点滴静注液100mg「サンド」は通常の市場流通下において3年間安定であることが推測された。 效果或疗效 （睾丸肿瘤，卵巢肿瘤，性腺外肿瘤）小细胞肺癌，恶性淋巴瘤，急性白血病，睾丸肿瘤，膀胱癌，滋养细胞疾病，生殖细胞瘤 联合治疗抗癌药物对其他恶性肿瘤 （肝脏恶性肿瘤尤因肉瘤家族肿瘤，横纹肌肉瘤，神经母细胞瘤，视网膜母细胞瘤，肝母细胞瘤等，原发性恶性肾肿瘤如肾母细胞瘤等）小儿恶性实体瘤 用法与用量 1。依托泊苷注射连续5天输液60〜 100mg/m2 （体表面积）每日剂量，3周停药。为一疗程，重复给药。 此外，剂量调整剂量可根据疾病和症状。 对于生殖细胞肿瘤，进行联合治疗，抗癌药物等标准已经确立，鬼臼乙叉甙100mg/m 2 （体表面积）每日剂量，是指连续5天输液我16天停药。为一疗程，重复给药。 和其他抗癌药物（肝脏恶性肿瘤尤因肉瘤家族肿瘤，横纹肌肉瘤，神经母细胞瘤，视网膜母细胞瘤，肝母细胞瘤等，原发性恶性肾肿瘤如肾母细胞瘤等） ，小儿恶性实体瘤如果中西医结合治疗 在结合抗癌药物 3，其他，管理的方法和剂量依托泊苷，是指连续3-5天输液100〜 150mg/m2 （体表面积）每日剂量，停药3周。为一疗程，重复给药。 此外，我适当减少其他疾病的症状，结合管理和天剂量的抗癌药物。 药理 通过形成稳定的复合物结合的拓扑异构酶Ⅱ ，抑制DNA的重组切，施加杀细胞作用。这种效应的强度依赖于暴露时间和浓度效应，细胞在G2 / M期，S期细胞周期的后期表现出高的灵敏度。它是有效的恶性淋巴瘤，小细胞肺癌。 包装 エトポシド点滴静注液100mg「サンド」：5mL×1バイアル、5mL×10バイアル **製造販売元 サンド株式会社 包装 エトポシド点滴静注液100mg「DK」 **製造販売元 共和薬品工業株式会社 包装 エトポシド点滴静注１００ｍｇ **製造販売元 大洋薬品工業株式 Toposar®, VePesid®, Etopophos® Other name: VP-16, Etoposide phosphate Chemocare.com uses generic names in all descriptions of drugs. VP-16 is the trade name for etoposide. VePesid and etopophos and toposar or etoposide phosphate are other names for etoposide. In some cases, health care professionals may use the trade name VP-16 or other names VePesid or etopophos or toposar or etoposide phosphate when referring to the generic drug name etoposide. Drug type:  Etoposide is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug.  This medication is classified as a "plant alkaloid" and "topoisomerase II inhibitor."  (For more detail, see "How this drug works" section below). What this drug is used for: •Testicular, bladder, prostate, lung, stomach, and uterine, cancers.  Hodgkin's and non-Hodgkin's lymphoma, mycosis fungoides, Kaposi's sarcoma, Wilm's tumor, rhabdomyosarcoma, Ewing's sarcoma, neuroblastoma, brain tumors. •It also may be given as high-dose therapy in bone marrow transplant setting. Note:  If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful. How this drug is given: •In tablet form by mouth. •As an infusion into the vein (intravenous, IV), as a short infusion or as a continuous infusion over 24 hours. •Etoposide is considered an irritant.  An irritant is a chemical that can cause inflammation of the vein through which it is given.  If the medication escapes from the vein it can cause tissue damage.  The nurse or doctor who gives this medication must be carefully trained.  If you experience pain or notice redness or swelling at the IV site while you are receiving etoposide, alert your health care professional immediately.  •The amount of etoposide that you will receive and the method it is given depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition being treated.  Your doctor will determine your dose, schedule and how it will be given. Side effects: Important things to remember about the side effects of etoposide: •Most people do not experience all of the side effects listed. •Side effects are often predictable in terms of their onset and duration. •Side effects are almost always reversible and will go away after treatment is complete. •There are many options to help minimize or prevent side effects. •There is no relationship between the presence or severity of side effects and the effectiveness of the medication. •The side effects of etoposide and their severity depend on how much of the drug is given.  In other words, high doses may produce more severe side effects. The following side effects are common (occurring in greater than 30%) for patients taking etoposide: •Low white blood cell count. (This can increase your risk for infection). •Low platelet count (This can increase your risk of bleeding). Nadir: Meaning low point, nadir is the point in time between chemotherapy cycles in which you experience low blood counts. Onset: 5-7 days Nadir: 7-14 days Recovery: 21-28 days •Hair loss •Menopause (chemotherapy induced) •Loss of fertility.  Meaning, your ability to conceive a child may be affected by etoposide. Discuss this issue with your health care provider.  •Nausea and vomiting (especially at high-doses) •Low blood pressure (if the drug is infused too fast) These side effects are less common, meaning they occur in 10-29 percent of patients receiving etoposide: •Mouth sores (especially at high doses) •Diarrhea (especially at high doses) •Poor appetite •Radiation recall (see skin reactions) Other side effects: •Metallic taste during infusion of drug •Inflammation at injection site •Peripheral neuropathy (numbness in your fingers and toes) may occur with repeated doses. This is a rare side effect but can be irreversible.  Report numbness or tingling of feet or hands to your health care provider. Delayed effects: •There is a slight risk of developing a blood cancer such as leukemia years after taking etoposide.  Talk to your doctor about this risk. Not all side effects are listed above, some that are rare (occurring in less than 10% of patients) are not listed here.  However, you should always inform your health care provider if you experience any unusual symptoms. When to contact your doctor or health care provider: Contact your health care provider immediately, day or night, if you should experience any of the following symptoms: •Fever of 100.4° F (38° C) or higher, chills (possible signs of infection).